Moffitt Cancer Center | Strategic Alliance Partners

April 19, 2023

Anna C. Pavlick, DO, overviews systemic therapy options for patients with unresectable or metastatic CSCC.

April 18, 2023

Turab J. Mohammed, MD, discusses challenges associated with the diagnosis of blastic plasmacytoid dendritic cell neoplasm, and strategies to improve early diagnosis of this disease.

April 12, 2023

Nikhil Khushalani, MD, discusses the multidisciplinary team approach to treating patients with cutaneous squamous cell carcinoma.

April 12, 2023

Skin cancer experts discuss prognosis and unmet needs in the cutaneous squamous cell carcinoma and melanoma treatment spaces.

April 12, 2023

A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.

April 12, 2023

Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.

April 06, 2023

Andrew Kuykendall, MD, discusses agents currently in development for patients with systemic mastocytosis and how these investigational therapies may fit into the overall treatment paradigm for this disease.

April 05, 2023

Andrew Kuykendall, MD, discusses the occurrence and management of adverse effects associated with midostaurin and avapritinib in patients with advanced systemic mastocytosis.

April 05, 2023

Andrew Kuykendall, MD, discusses the importance of testing for mutations in KIT and other genes in patients with systemic mastocytosis.

April 05, 2023

Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.

April 05, 2023

Expert panelists consider the broader evolution of therapy in resectable stage II-IV cutaneous squamous cell carcinoma.

March 31, 2023

A panel of skin cancer experts give an overview of cutaneous squamous cell carcinoma and melanoma.

March 29, 2023

Expert perspectives on real-world, in-practice identification and management of patients with resectable CSCC.

March 29, 2023

Panelists round out their review of staging and risk stratification in CSCC by considering how each affects the selection of optimal surgical strategies.

March 23, 2023

Frontline treatments that achieve transfusion independence are of paramount importance for patients with lower-risk myelodysplastic syndrome.

March 22, 2023

Following their discussions on staging and risk stratification in CSCC, key opinion leaders work to define resectability in cutaneous squamous cell carcinoma.

March 22, 2023

Expert panelists share their perspectives on best strategies to risk stratify patients diagnosed with cutaneous squamous cell carcinoma.

March 15, 2023

A review of current staging systems used to categorize CSCC, particularly those from the American Joint Committee on Cancer and Brigham and Women's Hospital.

March 15, 2023

Opening their discussion on resectable cutaneous squamous cell carcinoma (CSCC), expert panelists elucidate its current incidence and known risk factors.

March 06, 2023

Drs Khushalani, Dietrich, Luke, and Patel discuss the nuances of defining resectability in cutaneous squamous cell carcinoma, the evolving treatment paradigm of resectable disease, and how to translate updated data with cemiplimab into clinical practice.